The Mixed Lineage Leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription

Cancer Research

Volumn 72, Issue 8, 2012, Pages 1929-1934

  Mak, Anthony B ^a   Nixon, Allison M L ^a   Moffat, Jason ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; TRANSCRIPTION FACTOR AF4; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AF4 GENE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER GROWTH; CELL STRAIN CACO 2; CELL STRAIN HEK293; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; FUSION GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MIXED LINEAGE LEUKEMIA GENE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE;

ANTIGENS, CD; BLOTTING, WESTERN; CACO-2 CELLS; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PEPTIDES; RNA INTERFERENCE; TRANSCRIPTION, GENETIC;

EID: 84860152153     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3589     Document Type: Article

References (21)

1. Ferrandina G, Petrillo M, Bonanno G, Scambia G. Targeting CD133 antigen in cancer. Expert Opin Ther Targets 2009;13:823-37.
2. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med 2008;86:1025-32.
3. Kemper K, Sprick MR, de BM, Scopelliti A, Vermeulen L, Hoek M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010;70:719-29.
4. Shmelkov SV, Jun L, St CR, McGarrigle D, Derderian CA, Usenko JK, et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 2004;103:2055-61. (Pubitemid 38326220)
5. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009;28:209-18.
6. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S, et al. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 2008;18:1037-46.
7. Yi JM, Tsai HC, Glockner SC, Lin S, Ohm JE, Easwaran H, et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 2008;68:8094-103.
8. Tabu K, Kimura T, Sasai K, Wang L, Bizen N, Nishihara H, et al. Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol Cancer 2010;9:39.
9. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006;124:1283-98.
10. Mak AB, Blakely KM, Williams RA, Penttila PA, Shukalyuk AI, Osman KT, et al. CD133 N-glycosylation processing contributes to cell-surface recognition of the primitive cell marker AC133. J Biol Chem 2011;286:41046-56.
11. Thomas M, Gessner A, Vornlocher HP, Hadwiger P, Greil J, Heidenreich O. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 2005;106:3559-66. (Pubitemid 41609194)
12. Mak AB, Ni Z, Hewel JA, Chen GI, Zhong G, Karamboulas K, et al. A lentiviral functional proteomics approach identifies chromatin remodeling complexes important for the induction of pluripotency. Mol Cell Proteomics 2010;9:811-23.
13. De PK, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A, et al. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 2006;7:R84.
14. You Z, Bailis JM. DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints. Trends Cell Biol 2010;20:402-9.
15. Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, et al. Essential gene profiles in breast, pancreas and ovarian cancer cells. Cancer Discovery 2012;2:95-6.
16. Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010;17:198-212.
17. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev 2008;22:3403-8.
18. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008;14:355-68.
19. Wuchter C, Ratei R, Spahn G, Schoch C, Harbott J, Schnittger S, et al. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica 2001;86:154-61. (Pubitemid 32216088)
20. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood 2009;113:3287-96.
21. Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008;26:3008-17.